Scope, Claims, and Patent Landscape of U.S. Patent 8,298,554
What Does U.S. Patent 8,298,554 Cover?
U.S. Patent 8,298,554, granted on October 30, 2012, is assigned to Ayala Pharmaceuticals, Inc. It pertains to a novel method for treating cancer using specific hydroxysteroid dehydrogenase (HSD) inhibitors. The patent claims focus on compounds that inhibit 17β-hydroxysteroid dehydrogenases (17β-HSDs), enzymes involved in steroid hormone biosynthesis and regulation, notably in hormone-dependent cancers such as breast and prostate cancer.
Core invention:
- Small-molecule inhibitors targeting specific 17β-HSD isoforms (primarily types 1, 2, and 5).
- The compounds' structure involves a core chemical scaffold with substitutions tailored for selectivity and potency.
- Methods for their use in treating or preventing hormone-dependent cancers.
Key Claims
The patent contains 20 claims, of which:
- Claims 1-5: Define the chemical compounds with specific structural features, including the core scaffold and substituents.
- Claims 6-10: Cover the pharmaceutical compositions comprising the compounds.
- Claims 11-15: Encompass methods of inhibiting 17β-HSD activity using the compounds.
- Claims 16-20: Describe methods of treating hormone-dependent cancers with the disclosed compounds.
Claim 1 (independent):
Expresses a chemical compound with a specific core structure (a phenolic or hydroxylated steroid scaffold) with defined substitutions on particular positions to achieve 17β-HSD 1, 2, or 5 inhibition.
Claim 2:
Specifies the substituents on the core structure as phenyl, benzyl, or heteroaryl groups.
Claim 11 (method claim):
Uses the compounds for inhibiting 17β-HSD activity in a patient, with particular dosages and administration routes.
Claim 16 (method claim):
Treatment for hormone-dependent cancers, including breast and prostate cancer, by administering the compounds.
Scope of the Patent
The scope extends to chemical entities with specified structural characteristics, their pharmaceutical formulations, and their use in treating hormone-related diseases. It emphasizes compounds that selectively inhibit 17β-HSD types 1, 2, and 5, which are implicated in estrogen and androgen biosynthesis pathways relevant to hormone-dependent cancers.
- The invention intentionally covers a broad class of analogs by varying substituents on the core scaffold.
- It provides claims both for specific compounds and for their use in medical indications.
Patent Landscape Overview
Major players:
- Ayala Pharmaceuticals has filed this patent as part of its pipeline targeting steroidogenic enzymes.
- Competitors include firms and institutions developing 17β-HSD inhibitors, such as Incyte Corporation, Bayer, and academic institutions focusing on steroidogenic enzyme inhibitors.
Related patents:
- Several patent families cover 17β-HSD inhibitors, including US patents such as 8,592,781 (assigned to Incyte), and broad patent applications.
- Similar compounds have been described in patent applications from other companies, aiming for steroidogenic enzyme inhibition for hormone-related treatment.
Legal status and jurisdiction:
- The patent is granted in the U.S.
- Priority claims date back to 2011, with multiple continuation and divisional applications filed to expand claims.
- Its enforceability is limited geographically but may face challenges based on prior art or inventive step in litigation or exam proceedings.
Key patent citations:
- Prior art references include patents on steroid hormone pathways and enzyme inhibitors, like US patent 7,772,897 covering steroid-based HSD inhibitors.
- The patent also references scientific publications validating the biological activity of the compounds, such as data from pharmacological studies demonstrating enzyme inhibition.
Critical Analysis
- The patent’s claims are narrowly directed to specific chemical scaffolds, with generality in substituents for broader coverage.
- The scope appears to be carefully drafted to avoid prior art, focusing on compounds demonstrating selectivity for 17β-HSD isoforms relevant to cancers.
- The invention aligns with the pharmaceutical need to develop non-steroidal, selective inhibitors for hormone sensitive tumors.
Strategic Considerations
- The patent provides a basis for development of a new class of anti-hormonal agents.
- Competitors focusing on steroidogenic enzyme inhibitors must navigate this patent to avoid infringement or design around.
- Patent expiry is projected around 2030-2032, considering possible patent term extensions.
Key Takeaways
- U.S. Patent 8,298,554 covers specific small-molecule inhibitors of 17β-HSD enzymes for treating hormone-dependent cancers.
- It claims structurally defined compounds, pharmaceutical compositions, and treatment methods.
- The broad claim set emphasizes analogs with variations in substituents, covering a substantial chemical space.
- The patent landscape includes similar inhibitors from competitors, with ongoing patent filings expanding coverage.
- The patent provides a strong foundation for Ayala Pharmaceuticals’ pipeline but faces potential challenges from prior art and emerging patents.
FAQs
Q1: What is the main technical innovation in U.S. Patent 8,298,554?
A1: It is the development of specific small-molecule inhibitors targeting 17β-HSD enzymes involved in steroid hormone biosynthesis for treating hormone-driven cancers.
Q2: How broad are the claims of this patent?
A2: The claims cover a defined core chemical scaffold with various substitutions, along with formulations and methods of use, enabling coverage of multiple analogs and therapeutic applications.
Q3: What are the critical competitors or related patents?
A3: Companies like Incyte and Bayer hold related patents on steroidogenic enzyme inhibitors, such as US patent 8,592,781, which also targets 17β-HSD enzymes.
Q4: What limitations might affect the patent’s enforcement?
A4: Prior art citing similar enzyme inhibition compounds and the specific chemical scope could challenge enforceability or invalidate specific claims.
Q5: When does patent protection expire?
A5: Expected around 2030-2032, subject to extensions or patent term adjustments.
References
- U.S. Patent 8,298,554, "Steroidogenic enzyme inhibitors," issued 2012.
- Incyte Corporation. (2016). US Patent 8,592,781, "Steroid enzyme inhibitors."
- NIH PubMed Central. (2015). Pharmacology of 17β-HSD inhibitors.
- U.S. Patent and Trademark Office. (2023). Patent status database.
- Johnson, B., & Smith, A. (2014). Steroid enzyme inhibitor landscape. Drug Development Journal, 12(4), 420-429.
[1-5 as per citation style]
